Form 4: ALX Oncology Director Corey S. Goodman Acquires Stock Options

Director Corey S. Goodman acquired stock options in ALX Oncology Holdings Inc. on June 13, 2024.

Summary

• On June 13, 2024, Corey S. Goodman, a director and 10% owner of ALX Oncology Holdings Inc. (ALXO), acquired stock options.
• The transaction involved the acquisition of 20,200 stock options with an exercise price of $8.44.
• These options vest in 12 equal monthly installments starting on the 13th day of each month, or the day before the next annual meeting of stockholders, and expire on June 12, 2034.
• Following the transaction, Goodman directly owns 20,200 derivative securities.

Sentiment

Score: 6

Explanation: Neutral sentiment as it's a routine transaction. The acquisition of stock options by a director is generally viewed as a positive sign, but it's not a major event.

Positives

• The acquisition of stock options by a director may signal confidence in the company's future performance.

Industry Context

This is a standard transaction for executives and directors in publicly traded companies, aligning their interests with those of shareholders through equity-based compensation.

Comparison to Industry Standards

• Stock option grants are a common form of executive compensation in the biotechnology industry, used by companies like Amgen, Gilead Sciences, and Regeneron to incentivize performance and retain key personnel.
• The vesting schedule of 12 months is fairly standard, aligning with typical industry practices for executive compensation packages.

Key Dates